Home » BIOGEN, GENENTECH AT ODDS OVER DRUG'S FATE
BIOGEN, GENENTECH AT ODDS OVER DRUG'S FATE
Genentech Inc. and Biogen Idec Inc. are embroiled in a dispute over the development of a second-generation version of their blockbuster drug Rituxan. Genentech of South San Francisco, Calif., plans to proceed with development of the compound
as a treatment for rheumatoid arthritis and another inflammatory disorder.
The
Boston Globe
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May